Cargando…

Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

OBJECTIVE: To describe the response to rituximab in patients with treatment-resistant chronic inflammatory demyelinating polyneuropathy (CIDP) with antibodies against paranodal proteins and correlate the response with autoantibody titers. METHODS: Patients with CIDP and IgG4 anti–contactin-1 (CNTN1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Querol, Luis, Rojas-García, Ricard, Diaz-Manera, Jordi, Barcena, Joseba, Pardo, Julio, Ortega-Moreno, Angel, Sedano, Maria Jose, Seró-Ballesteros, Laia, Carvajal, Alejandra, Ortiz, Nicolau, Gallardo, Eduard, Illa, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561230/ https://www.ncbi.nlm.nih.gov/pubmed/26401517 http://dx.doi.org/10.1212/NXI.0000000000000149

Ejemplares similares

Tacrolimus Combined with Corticosteroids Improved the Outcome of CIDP Patients with Autoantibodies Against Paranodal Proteins
por: Yang, Meng-ge, et al.
Publicado: (2022)

Severe CIDP-MGUS responsive to Rituximab
por: Posa, Andreas, et al.
Publicado: (2020)

Head and voice tremor improving with immunotherapy in an anti‐NF155 positive CIDP patient
por: Painous, Cèlia, et al.
Publicado: (2018)

The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis
por: Cortés‐Vicente, Elena, et al.
Publicado: (2018)

Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies
por: Siles, Ana M., et al.
Publicado: (2018)

Isotyping paranodal antibodies in inflammatory neuropathies: One step closer to precision care
por: Lleixà, Cinta, et al.
Publicado: (2020)

Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients
por: Nogales-Gadea, Gisela, et al.
Publicado: (2014)

Novel Immunological and Therapeutic Insights in Guillain-Barré Syndrome and CIDP
por: Querol, Luis, et al.
Publicado: (2021)

Muscle MRI in muscular dystrophies
por: Díaz-Manera, Jordi, et al.
Publicado: (2015)

Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy
por: De Simoni, Desiree, et al.
Publicado: (2020)

The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes
por: Feng, Yuan, et al.
Publicado: (2020)

Localization of the paranodal protein Caspr in the mammalian retina
por: O’Brien, Brendan J., et al.
Publicado: (2010)

Nodes of Ranvier and Paranodes in Chronic Acquired Neuropathies
por: Cifuentes-Diaz, Carmen, et al.
Publicado: (2011)

Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)
por: Querol, Luis, et al.
Publicado: (2020)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

The Misdiagnosis of CIDP: A Review
por: Allen, Jeffrey A.
Publicado: (2020)

Treatment Approaches for Atypical CIDP
por: Menon, Deepak, et al.
Publicado: (2021)

Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy
por: Querol, Luis, et al.
Publicado: (2017)

Glutamate Excitotoxicity Inflicts Paranodal Myelin Splitting and Retraction
por: Fu, Yan, et al.
Publicado: (2009)

GLIAL ANKYRINS FACILITATE PARANODAL AXOGLIAL JUNCTION ASSEMBLY
por: Chang, Kae-Jiun, et al.
Publicado: (2014)

The paranodal cytoskeleton clusters Na(+) channels at nodes of Ranvier
por: Amor, Veronique, et al.
Publicado: (2017)

Paranodal Axoglial Junctions, an Essential Component in Axonal Homeostasis
por: Ishibashi, Tomoko, et al.
Publicado: (2022)

CIDP mimics: a case series
por: Moshe-Lilie, Orly, et al.
Publicado: (2021)

Axo-Glial Interactions Regulate the Localization of Axonal Paranodal Proteins
por: Dupree, Jeffrey L., et al.
Publicado: (1999)

Methylglyoxal Disrupts Paranodal Axoglial Junctions via Calpain Activation
por: Griggs, Ryan B., et al.
Publicado: (2018)

Coordinated internodal and paranodal adhesion controls accurate myelination by oligodendrocytes
por: Elazar, Nimrod, et al.
Publicado: (2019)

Concentration of neddylation-related molecules in paranodal myelin of the peripheral nervous system
por: KAJIGAYA, Hitoshi, et al.
Publicado: (2016)

MRI biomarkers of proximal nerve injury in CIDP
por: Lichtenstein, Thorsten, et al.
Publicado: (2017)

Progress in Hematopoietic Stem Cell Transplantation for CIDP
por: Qin, Zhen, et al.
Publicado: (2020)

Editorial: Update on the Diagnosis and Management of CIDP Variants
por: Chroni, Elisabeth, et al.
Publicado: (2021)

The neurophysiological lesson from the Italian CIDP database
por: Spina, Emanuele, et al.
Publicado: (2021)

Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis
por: De Luna, Noemí, et al.
Publicado: (2017)

Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes
por: Fernández-Simón, Esther, et al.
Publicado: (2020)

An Oligodendrocyte Cell Adhesion Molecule at the Site of Assembly of the Paranodal Axo-Glial Junction
por: Tait, Steven, et al.
Publicado: (2000)

MRI Characterization of Paranodal Junction Failure and Related Spinal Cord Changes in Mice
por: Takano, Morito, et al.
Publicado: (2012)

Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy
por: Duchateau, Lena, et al.
Publicado: (2019)

Correction: Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy
por: Duchateau, Lena, et al.
Publicado: (2019)

Deregulated Fcγ receptor expression in patients with CIDP
por: Quast, Isaak, et al.
Publicado: (2015)

CIDP prognosis in patients with IVIG treatment‐related fluctuations
por: Cook, Melissa, et al.
Publicado: (2022)

Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy
por: Pascual-Goñi, Elba, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5247ug9388gvqhsqd2nja2g8iu